BRAF and thyroid cancer: However, the most recent American Thyroid Association (ATA) recommendations do not indicate a routine application of BRAF status for initial risk stratification in differentiated thyroid cancer due to a lack of evident confirmation of a direct influence of mutation on the increase in relapse risk.